Literatur
Berden A et al (2012) Diagnosis and management of ANCA associated vasculitis. BMJ 344:e326
Faurschou M et al (2008) Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35:100–105
Heijl C et al (2011) Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European vasculitis study group clinical trials. Ann Rheum Dis 70:1415–1421
Stone JH et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232
Cartin-Ceba R et al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s). Arthritis Rheum 64:3770–3778
Vollenhoven RF van (2012) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis (e-pub ahead)
Einhaltung ethischer Richtlinien
Interessenkonflikt. M. Zänker ist als Referent für die Firmen Roche, Abbott und MSD tätig und erhielt von diesen Firmen Beraterhonorare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zänker, M. Erhöhte Tumorinzidenz bei ANCA-assoziierten Vaskulitiden. Z. Rheumatol. 72, 921–922 (2013). https://doi.org/10.1007/s00393-013-1283-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-013-1283-x